{"id":"NCT01421459","sponsor":"Eli Lilly and Company","briefTitle":"A Study in Adults With Type 2 Diabetes","officialTitle":"A Prospective, Randomized, Double-Blind Comparison of a Long-Acting Basal Insulin Analog LY2963016 to Lantus in Adult Patients With Type 2 Diabetes Mellitus: The ELEMENT 2 Study","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-09","primaryCompletion":"2012-09","completion":"2012-09","firstPosted":"2011-08-22","resultsPosted":"2014-10-09","lastUpdate":"2014-12-18"},"enrollment":759,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes Mellitus, Type 2"],"interventions":[{"type":"DRUG","name":"LY2963016","otherNames":[]},{"type":"DRUG","name":"Lantus","otherNames":[]},{"type":"DRUG","name":"OAMs","otherNames":[]}],"arms":[{"label":"LY2963016 + OAMs","type":"EXPERIMENTAL"},{"label":"Lantus + OAMs","type":"ACTIVE_COMPARATOR"}],"summary":"The main purpose of this study is to compare the effectiveness and safety of LY2963016 versus Lantus in controlling blood sugar levels in combination with two or more oral diabetes medications.","primaryOutcome":{"measure":"Change From Baseline up to 24 Weeks in Hemoglobin A1c (HbA1c)","timeFrame":"Baseline, Endpoint (up to 24 weeks)","effectByArm":[{"arm":"LY2963016 + OAMs","deltaMin":-1.286,"sd":0.06},{"arm":"Lantus + OAMs","deltaMin":-1.338,"sd":0.06}],"pValues":[{"comp":"OG000 vs OG001","p":"0.403"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":6},"locations":{"siteCount":62,"countries":["United States","Czechia","France","Germany","Greece","Hungary","Mexico","Poland","Puerto Rico","South Korea","Spain","Taiwan"]},"refs":{"pmids":["29855972","29542012"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":15,"n":376},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Diarrhoea","Back pain","Influenza"]}}